Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 8 April 2019, 10:43 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
Start Your Day With a Sparkling Pop!

Containing 75 Lemons Worth of Vitamin C and 50% Less Calories!

TOKYO, Apr 8, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch its new carbonated beverage Chocola BB Sparkling Kiwi & Lemon Flavor, classified as a Food with Nutrient Function Claims, in Japan on Tuesday, April 9.


Chocola BB Sparkling Kiwi & Lemon Flavor is a new carbonated beverage classified by the Japanese Consumer Affairs Agency as a Food with Nutrient Function Claims (Niacin), and is the newest product flavor of the Chocola BB Sparkling series which has been well received mainly by working women since the series? initial launch in 2011. The drink contains five ingredients that help bring out women?s beauty from within, including 1500 mg of vitamin C which is equivalent to 75 lemons, in addition to vitamin B1, B6, iron, as well as niacin to help maintain the health of skin and mucosal membranes. Compared to the original Chocola BB Sparkling Grapefruit & Peach Flavor, calories have been reduced by 50% (24kcal).

By adding the new Chocola BB Sparkling Kiwi & Lemon Flavor with its fresh taste to the Chocola BB Sparkling lineup, consumers will be able to enjoy a choice between two flavors to match their personal needs for refreshment.

Eisai continues to provide the Chocola BB family of products to respond to the diverse needs of women and support a greater number of people to achieve health and beauty in their everyday lives.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 12, 2025 12:20 HKT/SGT
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: